ACTEMRA clinical study results
ACTEMRA clinical study results
Learn how to take ACTEMRA
Patient financial assistance
ACTEMRA® (tocilizumab) is a prescription medicine used to slow the decline in lung function in adults with systemic sclerosis–associated interstitial lung disease (SSc-ILD). It is thought to work by blocking IL-6 receptor, a key messenger that tells the immune system to attack healthy cells and may contribute to the signs and symptoms of SSc-ILD.
In SSc-ILD, ACTEMRA is given as a 162 mg subcutaneous injection once weekly. Intravenous administration is not approved for this indication.
Side effects are similar to its other uses: sinus infections, headache, higher blood pressure, and injection-site reactions. Serious risks include serious infections, gastrointestinal perforation, hepatotoxicity, neutropenia, thrombocytopenia, and hypersensitivity. Monitoring with CBC, liver enzymes, and lipid panels (4–8 weeks after starting, then periodically) is essential; screening for latent TB and hepatitis before initiation is required. Report fever, cough, worsening respiratory symptoms, abdominal pain, or signs of allergic reaction immediately. Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.